Loading
A phase 1/2 trial of Trastuzumab rezetecan, Carboplatin, Bevacizumab in ovarian cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer is a phase 1/2 interventional study registered as NCT06840002 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 150 participants planned, started 2025-03-18 and due to reach its primary completion in 2026-12. Interventions recorded: SHR-A1811, Carboplatin, Bevacizumab, Oxaliplatin for Injection, Paclitaxel injection. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Trastuzumab rezetecan, CAPOX (capecitabine, oxaliplatin), Jiangsu Hengrui Pharmaceuticals, Bevacizumab.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Paclitaxel / nab-paclitaxel.
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads).
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Bevacizumab, Topoisomerase-I inhibitors (and ADC payloads).
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads).
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/